News | May 03, 2024
Novartis to acquire Mariana Oncology for upfront US$ 1 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Sales reflect continued strong growth in oncology and vaccines
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
